Sulofenur
Sulofenur (LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models.
For research use only. We do not sell to patients.
- CAS No.: 110311-27-8
- Formula: C16H15ClN2O3S
- Molecular Weight:350.82
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Calcium Channel Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>20 μM
Compound: Sulofenur
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
[PMID: 21570750] |
| A549 | IC50 |
11.34 μM
Compound: LY-186641
|
In vitro cytotoxic activity against human lung carcinoma A549 cell line
In vitro cytotoxic activity against human lung carcinoma A549 cell line
|
10.1016/0960-894X(96)00463-5 |
| A549 | IC50 |
36.43 μM
Compound: 2
|
Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
|
[PMID: 9873387] |
| CCRF-CEM | IC50 |
11.2 μg/mL
Compound: 104 (LY-186641)
|
Concentration required to inhibit growth of CCRF-CEM cells in culture for 72 hr to 50% of control growth
Concentration required to inhibit growth of CCRF-CEM cells in culture for 72 hr to 50% of control growth
|
[PMID: 2391684] |
| CCRF-CEM | IC50 |
11.2 μg/mL
Compound: Sulofenur
|
In vitro cytotoxicity against CCRF-CEM cells
In vitro cytotoxicity against CCRF-CEM cells
|
[PMID: 9083492] |
| CCRF-CEM | IC50 |
32 μM
Compound: Sulofenur
|
Cytotoxicity against CCRF-CEM lymphocytic leukemia cell line
Cytotoxicity against CCRF-CEM lymphocytic leukemia cell line
|
[PMID: 10476861] |
| COLO 205 | IC50 |
23.06 μM
Compound: Sulofenur
|
Anticancer activity against human COLO205 cells by MTT assay
Anticancer activity against human COLO205 cells by MTT assay
|
[PMID: 21570750] |
| K562 | IC50 |
19.2 μM
Compound: Sulofenur
|
Anticancer activity against human K562 cells by MTT assay
Anticancer activity against human K562 cells by MTT assay
|
[PMID: 21570750] |
| K562 | IC50 |
50.08 μM
Compound: 2
|
Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay
Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay
|
[PMID: 9873387] |
| P388D1 | IC50 |
>100 μM
Compound: Sulofenur
|
Anticancer activity against mouse P388D1 cells by MTT assay
Anticancer activity against mouse P388D1 cells by MTT assay
|
[PMID: 21570750] |
| SK-MEL-2 | IC50 |
12.91 μM
Compound: LY-186641
|
In vitro cytotoxic activity against human melanoma SK-MEL-2 cell line
In vitro cytotoxic activity against human melanoma SK-MEL-2 cell line
|
10.1016/0960-894X(96)00463-5 |
| SK-OV-3 | IC50 |
222.9 μM
Compound: 2
|
Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay
Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay
|
[PMID: 9873387] |
| SK-OV-3 | IC50 |
78.2 μM
Compound: Sulofenur
|
Anticancer activity against human SKOV3 cells by MTT assay
Anticancer activity against human SKOV3 cells by MTT assay
|
[PMID: 21570750] |
Chemical Information
-
CAS No. 110311-27-8
-
Molecular Weight 350.82
-
Formula C16H15ClN2O3S
-
SMILES
O=S(C1=CC2=C(CCC2)C=C1)(NC(NC3=CC=C(Cl)C=C3)=O)=O
-
Synonyms
Diarylsulfonylurea; LY186641
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Gu H, et al. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment. Cancer Lett. 1996 Sep 10;106(2):199-205. [Content Brief]
[2]. Brown TD, et al. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. Anticancer Drugs. 1994 Apr;5(2):151-9. [Content Brief]
[3]. Ehlhardt WJ, et al. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs. J Pharm Sci. 1993 Jul;82(7):683-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz